Erratum: Programmed cell death 5 mediates HDAC3 decay to promote genotoxic stress response (Nature Communications (2015) 6 (7390) DOI:10.1038/ncomms8390);Programmed cell death 5 mediates HDAC3 decay to promote genotoxic stress response

Nature Communications

Volumn 6, Issue , 2015, Pages

  Choi, Hyo Kyoung ^a   Choi, Youngsok ^b   Park, Eun Sung ^a   Park, Soo Yeon ^a   Lee, Seung Hyun ^a   Seo, Jaesung ^a   Jeong, Mi Hyeon ^a   Jeong, Jae Wook ^c   Jeong, Jae Ho ^a   Lee, Peter C W ^d   Choi, Kyung Chul ^d   Yoon, Ho Geun ^a  

^a Yonsei University College of Medicine   (South Korea)

^b CHA University   (South Korea)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE 2 ALPHA; CASEIN KINASE II; CASPASE 3; ETOPOSIDE; HISTONE DEACETYLASE 3; MEMBRANE PROTEIN; PROGRAMMED CELL DEATH 5; PROTEASOME; PROTEIN P53; SERINE; UBIQUITIN; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; HISTONE DEACETYLASE; IMPORTIN 13 PROTEIN, MOUSE; IMPORTIN 13, HUMAN; KARYOPHERIN; PDCD5 PROTEIN, HUMAN; PDCD5 PROTEIN, MOUSE; TUMOR PROTEIN;

APOPTOSIS; CANCER; ENZYME ACTIVITY; GENOTOXICITY; INHIBITION; PROTEIN; TUMOR;

ARTICLE; CANCER CELL; CANCER PATIENT; CANCER PROGNOSIS; CARCINOGENICITY; CELL NUCLEUS; CONTROLLED STUDY; GENE DELETION; GENOTOXICITY; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; STOMACH CANCER; STRESS; ANIMAL; CANCER TRANSPLANTATION; CHROMATIN IMMUNOPRECIPITATION; DNA DAMAGE; FIBROBLAST; GENE EXPRESSION PROFILING; GENETICS; HCT 116 CELL LINE; HUMAN; IMMUNOPRECIPITATION; KNOCKOUT MOUSE; MASS SPECTROMETRY; METABOLISM; PHOSPHORYLATION; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; STOMACH TUMOR; TUMOR CELL LINE; TUNEL ASSAY;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CASEIN KINASE II; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DNA DAMAGE; FIBROBLASTS; GENE EXPRESSION PROFILING; HCT116 CELLS; HISTONE DEACETYLASES; HUMANS; IMMUNOPRECIPITATION; IN SITU NICK-END LABELING; KARYOPHERINS; MASS SPECTROMETRY; MICE; MICE, KNOCKOUT; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROGNOSIS; PROTEASOME ENDOPEPTIDASE COMPLEX; REAL-TIME POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84935850765     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9225     Document Type: Erratum

References (44)

1. Vazquez, A., Bond, E. E., Levine, A. J. & Bond, G. L. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat. Rev. Drug Discov. 7, 979-987 (2008).
2. Vousden, K. H. p53: death star. Cell 103, 691-694 (2000).
3. Bode, A. M. & Dong, Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 4, 793-805 (2004).
4. Kruse, J. P. & Gu, W. Modes of p53 regulation. Cell 137, 609-622 (2009).
5. Oliner, J. D. et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362, 857-860 (1993).
6. Ito, A. et al. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 21, 6236-6245 (2002).
7. Narita, N. et al. Suppression of histone deacetylase 3 (HDAC3) enhances apoptosis induced by paclitaxel in human maxillary cancer cells in vitro and in vivo. Biochem. Biophys. Res. Commun. 396, 310-316 (2010).
8. Zeng, L. et al. HDAC3 is crucial in shear- and VEGF-induced stem cell differentiation toward endothelial cells. J. Cell Biol. 174, 1059-1069 (2006).
9. Monte, M. et al. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc. Natl Acad. Sci. USA 103, 11160-11165 (2006).
10. Kim, Y. et al. miR-326-Histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs. J. Biol. Chem. 289, 28019-28039 (2014).
11. Xia, Y. et al. c-Jun downregulation by HDAC3-dependent transcriptional repression promotes osmotic stress-induced cell apoptosis. Mol. Cell 25, 219-232 (2007).
12. Escaffit, F. et al. Cleavage and cytoplasmic relocalization of histone deacetylase 3 are important for apoptosis progression. Mol. Cell. Biol. 27, 554-567 (2007).
13. Pilarsky, C., Wenzig, M., Specht, T., Saeger, H. D. & Grutzmann, R. Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia 6, 744-750 (2004).
14. Liu, H. et al. TFAR19, a novel apoptosis-related gene cloned from human leukemia cell line TF-1, could enhance apoptosis of some tumor cells induced by growth factor withdrawal. Biochem. Biophys. Res. Commun. 254, 203-210 (1999).
15. Dobson, A. T. et al. The unique transcriptome through day 3 of human preimplantation development. Hum. Mol. Genet. 13, 1461-1470 (2004).
16. Li, H. et al. Reduced expression of PDCD5 is associated with high-grade astrocytic gliomas. Oncol. Rep. 20, 573-579 (2008).
17. Spinola, M. et al. Association of the PDCD5 locus with lung cancer risk and prognosis in smokers. J. Clin. Oncol. 24, 1672-1678 (2006).
18. Yang, Y. H. et al. Expression of programmed cell death 5 gene involves in regulation of apoptosis in gastric tumor cells. Apoptosis 11, 993-1001 (2006).
19. Xu, H. Y. et al. Transfection of PDCD5 effect on the biological behavior of tumor cells and sensitized gastric cancer cells to cisplatin-induced apoptosis. Dig. Dis. Sci. 57, 1847-1856 (2012).
20. Yin, A., Jiang, Y., Zhang, X., Zhao, J. & Luo, H. Transfection of PDCD5 sensitizes colorectal cancer cells to cisplatin-induced apoptosis in vitro and in vivo. Eur. J. Pharmacol. 649, 120-126 (2010).
21. Xu, L. et al. PDCD5 interacts with Tip60 and functions as a cooperator in acetyltransferase activity and DNA damage-induced apoptosis. Neoplasia 11, 345-354 (2009).
22. Wang, Y. et al. An alternative form of paraptosis-like cell death, triggered by TAJ/TROY and enhanced by PDCD5 overexpression. J. Cell Sci. 117, 1525-1532 (2004).
23. Rui, M., Chen, Y., Zhang, Y. & Ma, D. Transfer of anti-TFAR19 monoclonal antibody into HeLa cells by in situ electroporation can inhibit the apoptosis. Life Sci. 71, 1771-1778 (2002).
24. Xu, L. et al. PDCD5 interacts with p53 and functions as a positive regulator in the p53 pathway. Apoptosis 17, 1235-1245 (2012).
25. Choi, H. K. et al. Reversible SUMOylation of TBL1-TBLR1 regulates betacatenin-mediated Wnt signaling. Mol. Cell 43, 203-216 (2011).
26. Li, J. et al. Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J. 19, 4342-4350 (2000).
27. Tang, Y., Zhao, W., Chen, Y., Zhao, Y. & Gu, W. Acetylation is indispensable for p53 activation. Cell 133, 612-626 (2008).
28. Essers, P. B. et al. The von Hippel-Lindau tumor suppressor regulates programmed cell death 5-mediated degradation of Mdm2. Oncogene 34, 771-779 (2014).
29. Salvi, M. et al. Programmed cell death protein 5 (PDCD5) is phosphorylated by CK2 in vitro and in 293T cells. Biochem. Biophys. Res. Commun. 387, 606-610 (2009).
30. Nardozzi, J. D., Lott, K. & Cingolani, G. Phosphorylation meets nuclear import: a review. Cell Commun. Signal. 8, 32 (2010).
31. Marchler-Bauer, A. et al. CDD: conserved domains and protein threedimensional structure. Nucleic Acids Res. 41, D348-D352 (2013).
32. Zhang, X. et al. Clinical and prognostic significance of lost or decreased PDCD5 expression in human epithelial ovarian carcinomas. Oncol. Rep. 25, 353-358 (2011).
33. Zhang, F., Shi, Y., Wang, L. & Sriram, S. Role of HDAC3 on p53 expression and apoptosis in T cells of patients with multiple sclerosis. PLoS ONE 6, e16795 (2011).
34. Calvert, M. E. et al. Phosphorylation by casein kinase 2 regulates Nap1 localization and function. Mol. Cell. Biol. 28, 1313-1325 (2008).
35. Mueller, T. et al. CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3. Hum. Mol. Genet. 18, 3334-3343 (2009).
36. Trembley, J. H., Wang, G., Unger, G., Slaton, J. & Ahmed, K. Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. Cell. Mol. life Sci. 66, 1858-1867 (2009).
37. Walsh, J. G. et al. Executioner caspase-3 and caspase-7 are functionally distinct proteases. Proc. Natl Acad. Sci. USA 105, 12815-12819 (2008).
38. Kirschbaum, M. et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J. Clin. Oncol. 29, 1198-1203 (2011).
39. Minami, J. et al. Histone deacetylase 3 (HDAC3) as a novel therapeutic target in multiple myeloma. Leukemia 28, 680-689 (2013).
40. Suzuki, T. et al. Identification of highly selective and potent histone deacetylase 3 inhibitors using click chemistry-based combinatorial fragment assembly. PLoS ONE 8, e68669 (2013).
41. Wenger, C. D., Phanstiel, D. H., Lee, M. V., Bailey, D. J. & Coon, J. J. COMPASS: a suite of pre- and post-search proteomics software tools for OMSSA. Proteomics 11, 1064-1074 (2011).
42. Bolstad, B. M., Irizarry, R. A., Astrand, M. & Speed, T. P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19, 185-193 (2003).
43. Lee, Y. J. et al. Nuclear receptor PPARgamma-regulated monoacylglycerol O-acyltransferase 1 (MGAT1) expression is responsible for the lipid accumulation in diet-induced hepatic steatosis. Proc. Natl Acad. Sci. USA 109, 13656-13661 (2012).
44. Luo, J. et al. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat. Protoc. 2, 1236-1247 (2007).